Events and Presentations

21-23 September 2009
Molecular Graphics Modelling Society: Fragment-based lead discovery FBLD 2009
York
presenting

19-24 July 2009
Gordon Research Conferences: Computer Aided Drug Design
Tilton, NH
presenting

29 May - 2 June 2009
American Society for Clinical Oncology (ASCO) Annual Meeting 2009
Orlando
presenting

• A Phase I Study Of AT9283, An Aurora Kinase Inhibitor In Patients With Refractory Solid Tumours

18-21 May 2009
2009 BIO International Convention
Atlanta

18-22 April 2009
American Association for Cancer Research (AACR) 100th Annual Meeting 2009
Denver
presenting

• Significance of long term pharmacodynamic actions of the HSP90 inhibitor AT13387
• Identification of a biologically effective dose of AT7519, a cyclin dependent kinase inhibitor, in a phase I study.

7-8 April 2009
CHI: Fragment Based Techniques
San Diego
presenting

22-26 March 2009
237th American Chemical Society National Meeting & Exposition
Salt Lake City
presenting

4-5 March 2009
Royal Society of Chemistry. Fragments 2009: The 2nd BMCS Fragment-based Drug Discovery Meeting
Alderley Park, Cheshire
presenting

3-4 March 2009
Informa Life Sciences: 8th Annual Protein Kinase Conference
Barcelona
presenting

23-24 February 2009
SMI: Advances and Progress in Drug Design VIII
London
presenting. Computational Methods In Fragment Bsed Drug Design

16-18 February 2009
BioBusiness 2009
Geneva
presenting

6-9 December 2008
50th ASH Annual Meeting and Exposition
San Francisco
presenting

• Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models
• Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways
• AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

6 November 2008
UK-QSAR and ChemoInformatics Group: Autumn Meeting 2008
Welwyn Garden City
presenting

21-24 October 2008
20th EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”
Geneva
presenting

• AT13387, A Fragment Derived Clinical Candidate is Active in Lung and Melanoma Models
• Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity
• Identification of potent, selective JAK2 inhibitors using a fragment-based screening approach

18-22 October 2008
BIT's 6th International Congress of Drug Discovery Sciences and Technology
Beijing
presenting

14 October 2008
Sofinnova Japan Biopharma Partnering Conference
Tokyo
presenting

12-14 October 2008
16th Annual BioPartnering Europe
London

9 October 2008
Cutting Edge Approaches to Drug Design
London
presenting

16-17 September 2008
Informa conference on Structure based Drug Design
Budapest, Hungary
presenting

20-23 July 2008
AACR Centennial Conference - Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
California
presenting

• Biomarker Identification for AT9283: A Multitargeted Kinase Inhibitor with Aurora A and B Activities from Pre-clinical Models to Clinical Trials

17-20 June 2008
BIO 2008 International Convention
San Diego
presenting

30 May-3 June 2008
44th ASCO Annual Meeting
Chicago
presenting

• A Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of AT7519
• A Dose Escalation and Pharmacodynamic Study of AT9283 in Patients with Refractory Solid Tumours
• A Phase I and Pharmacodynamic Trial of AT9283, an Aurora Kinase Inhibitor in Patients with Refractory Leukemia

19-22 May 2008
Informa's Annual InfoTech for Pharma and Biotech
Basel
presenting

7-9 May 2008
ERBI's 10th Anniversary Cambridge BioPartnering Exchange
Cambridge
presenting

28-29 April 2008
CHI Drug Discovery Chemistry
San Diego
presenting

21-22 April 2008
Proteinase 2008 From Molecules to Medicines
London
presenting

12-16 April 2008
American Association for Cancer Research (AACR) Annual Meeting 2008
San Diego, CA
presenting

• AT9283, a potent inhibitor of Bcr-Abl T315I, is active in CML models
• Development of inhibitors of the fibroblast growth factor receptor (FGFr) kinase using a fragment based approach

7-9 April 2008
Bio-Europe Spring
Madrid
presenting

29 March-3 April 2008
2008 Keystone Symposium Computer-Aided Drug Design
Colorado
presenting

10-12 March 2008
Informa Life Science 7th Annual Protein Kinases Conference
Berlin
presenting

18-20 February 2008
Fragment-based Lead Discovery Conference 2008
San Diego
presenting

11-13 Februray 2008
BIO CEO & Investor Conference
New York
presenting

6 February 2008
DMDG Spring Meeting: “Discovery and development of new therapies for cancer - a DMPK perspective.”
Cambridge
Astex hosting

8-11 December 2007
The American Society of Hematology 49th Annual Meeting and Exposition
Atlanta, Georgia
presenting

• A Phase I trial of AT9283, a multitargeted kinase inhibitor in patients with refractory hematological malignancies
• AT9283, a potent inhibitor of JAK2 is active in JAK2 V617F MPD models
• AT7519, a potent CDK inhibitor is active in leukemia models and primary CLL patient samples

22-26 October 2007
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
San Francisco
presenting

• Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines
• AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumour activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.

12-14 April 2007
AACR Annual Meeting 2007
Los Angeles
presenting

• Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.